Cipla Ltd Share Price
(CIPLA)
₹1442.2
as on 04:01PM, 28 Mar 2025
Cipla Performance
Day's Low
Day's High
₹1,434.45Day's Price Range₹1,478.6552 Week's Low
52 Week's High
₹1,317.2552-Week Price Range₹1,702.05
| Returns % | |
| 1 Month Return | + 5.36 % |
| 3 Month Return | -2.53 % |
| 1 Year Return | -0.94 % |
| Market Stats | |
| Previous Close | ₹1,482.90 |
| Open | ₹1,475.00 |
| Volume | 14.96L |
| Upper Circuit | ₹1,631.15 |
| Lower Circuit | ₹1,334.65 |
| Market Cap | ₹1,19,761.54Cr |
Cipla Fundamentals
P/E Ratio
24
PEG Ratio
1.51
Market Cap
₹1,19,761.54 Cr
P/B Ratio
4.31
EPS
51.47
Dividend Yield
0.87
Sector
Pharmaceuticals
ROE
15.5
Mutual Fund Holdings of Cipla
Cipla Analyst Rating
based on 37 analysts
64.86%
Buy
21.62%
Hold
13.51%
Sell
Based on 37 analysts offering long term price targets for Cipla. An average target of ₹1642.97
Source: S&P Global Market Intelligence
Cipla Share analysis
Cipla price forecast by 37 analysts
Upside of10.79%
High
₹1875
Target
₹1642.97
Low
₹1204
Cipla target price ₹1642.97, a slight upside of 10.79% compared to current price of ₹1442.2. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Cipla revenue growth forecast
Expected growth rate Q1, FY2027:24.66%
Forecast
Actual
Including amortisation and stock based compensations
Cipla EPS growth forecast
EPS estimate Q1, FY2027:30.28%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Cipla Ltd
Cipla's Nifty Weightage Increase Expected - 26 Mar, 2025
Cipla is anticipated to see an increase in its weightage in the Nifty 50 index, leading to an inflow of approximately $29 million.Cipla Positioned for Growth Amid Challenges - 22 Mar, 2025
Cipla faces moderate headwinds but is well-positioned for long-term growth with a strong product pipeline and strategic consolidation in Africa. The stock is recommended for accumulation at current valuations.Cipla Stock Shows Bullish Momentum and New Agreement - 19 Mar, 2025
Cipla has signed a licensing agreement with Formosa Pharmaceuticals and demonstrated a strong breakout above trendline resistance, indicating bullish momentum despite a minor price dip.Cipla Secures Licensing Deal, Shares Rise - 18 Mar, 2025
Cipla has entered an exclusive licensing agreement with Formosa Pharmaceuticals for clobetasol propionate ophthalmic suspension, enhancing its ophthalmology portfolio across 11 countries. The stock saw a 2% increase following the announcement, reflecting positive market sentiment.Cipla Faces Consolidation After Price Decline - 17 Mar, 2025
Cipla Ltd is currently in a phase of sideways consolidation following a 19.7% drop from its all-time high. The stock is trading between support at Rs 1,366 and resistance at Rs 1,502, requiring a decisive break to establish a clear trend.IPA Proposes Zero Tariff on US Pharma Imports - 07 Mar, 2025
The Indian Pharmaceutical Alliance has recommended to the government to eliminate tariffs on imports of pharmaceutical products from the US, potentially benefiting companies like Cipla.Mutual Funds Increase Stake in Cipla Amid Price Recovery - 06 Mar, 2025
Mutual funds raised their stake in Cipla to 20.5%, up from 17.5%. The stock closed 1.21% higher at Rs 1,418.75, recovering from an 8% loss last quarter.Cipla CEO Addresses Tariff Concerns at Summit - 28 Feb, 2025
Cipla's Global CEO, Umang Vohra, stated that tariffs should not influence Indian drug companies' decisions, highlighting the need for adaptive manufacturing models in the future.Cipla Confident Amid US Tariffs and Growth Prospects - 26 Feb, 2025
Cipla's CEO, Umang Vohra, reassures that US tariffs won't hinder Indian generics. He emphasizes growth potential in GLP-1 and semaglutide, with a positive outlook on earnings.
Insights on Cipla Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 4 quarters, 6.41K Cr → 7.29K Cr (in ₹), with an average increase of 4.2% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 17.44% to 20.42% in Dec 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 939.04 Cr → 1.57K Cr (in ₹), with an average increase of 15.6% per quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 16.08% to 16.41% in Dec 2024 quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.0% return, outperforming this stock by 91.2%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 70.5% return, outperforming this stock by 71.4%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 28.74% to 26.60% in Dec 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 3 months, CIPLA stock has moved down by -2.5%
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 30.86% to 29.13% in Dec 2024 quarter
Cipla News
Cabinet Approves $2.7 Billion for Local Electronics Manufacturing
Ajai Chowdhry, co-founder of HCL Technologies Ltd and chairman of Epic Foundation, said this (the scheme) will enable much higher value addition in the country for electronics manufacturing, and will attract more investments in system products—as local availability will enable just-in-time manufacturing.28 Mar, 2025 08:58 PMTop Four IT Firms Lose $50 Billion in Market Capitalization
Indias top four IT companies— Tata Consultancy Services , Infosys, HCL Technologies and Wipro—have collectively lost $50.5 billion (₹4.3 lakh crore) in market capitalisation during the first three months of 2025, driven by concerns over slowing global demand and cautious client spending. HCL Technologies lost $10.3 billion during the same period. Shares of HCL Technologies fell nearly 17%, marking their steepest decline in the last ten quarters. Consequently, HCL Technologies has the highest Sell rating among the three, with 10 out of 45 analysts advising a Sell.28 Mar, 2025 08:40 PMRoshni Nadar: India's Wealthiest Woman and HCL Technologies Chairperson
Roshni Nadar, the Chairperson of HCL Technologies, has made history as the first Indian woman to feature on the top 10 list of the worlds richest women released by Hurun. Nadar has a staggering net worth of Rs 3.5 lakh crore (US$ 40 billion), a large portion of which she inherited after her father and HCL founder Shiv Nadar transferred the majority stake in the company to her. She is now the third-richest person in India. HCL Technologies, a global tech giant with a market valuation of $48 billion.28 Mar, 2025 04:43 PMCipla Financials
Cipla Index Inclusions
Cipla Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 29.13% | ||
| Foreign Institutions | 26.6% | ||
| Mutual Funds | 20.42% | 17.09 | |
| Retail Investors | 16.41% | 2.06 | |
| Others | 7.44% | 8.01 |
Cipla Key Indicators
Cipla Valuation
Cipla in the last 5 years
Lowest (18.11x)
March 19, 2020
Today (24.00x)
March 27, 2025
Industry (53.19x)
March 27, 2025
Highest (42.80x)
January 23, 2018
Cipla Earnings and Dividends
Cipla Ltd Earnings Results
Cipla Ltd’s net profit jumped 48.74% since last year same period to ₹1,570.51Cr in the Q3 2024-2025. On a quarterly growth basis, Cipla Ltd has generated 20.57% jump in its net profits since last 3-months.
Read More about Earnings ResultsCipla Ltd Dividends May,2024
In the quarter ending March 2024, Cipla Ltd has declared dividend of ₹13 - translating a dividend yield of 1.49%.
Read More about Dividends
Cipla Technicals Summary
Bearish
Neutral
Bullish
Cipla Ltd is currently in a Bearish trading position according to technical analysis indicators.
Cipla Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹1,19,761.54 Cr | 48.69% | 0.50 | ₹4,155 Cr | ₹25,774 Cr | |
| HOLD | ₹1,55,900.41 Cr | 42.02% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,09,419.57 Cr | 45.98% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹41,486.73 Cr | 5.08% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹26,440.93 Cr | -2.36% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Cipla
Cipla's operations include manufacturing, marketing, and distribution of pharmaceuticals, biotechnology, and consumer healthcare products. Its top products include respiratory, anti-infectives, cardiovascular, and oncology drugs. Popular brands include Asthalin, Cipcal, Cifran, and Erythromycin. Cipla also manufactures nutraceuticals, herbal products, and over-the-counter medicines.
Revenue: ₹6,961.60Cr as on December 2024 (Q4 24)
Net Profit: ₹1,583.72Cr as on December 2024 (Q4 24)
Listing date: 03 Nov, 1994
Chairperson Name: Y K Hamied
| Organisation | Cipla |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Cipla Ltd
What is Cipla Ltd price today?
Cipla Ltd share price today stands at ₹1442.2, Open: ₹1475, Previous Close: ₹1482.9, High: ₹1478.65, Low: ₹1434.45, 52 Week High: ₹1702.05, 52 Week Low: ₹1317.25.
How to Buy Cipla Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Cipla Ltd shares
What are today's traded volumes of Cipla Ltd?
Today's traded volume of Cipla Ltd(CIPLA) is 14.96L.
What is today's market capitalisation of Cipla Ltd?
Today's market capitalisation of Cipla Ltd(CIPLA) is ₹119761.54Cr.
What is the 52 Week High and Low Range of Cipla Ltd?
How much percentage Cipla Ltd is down from its 52 Week High?
Cipla Ltd (CIPLA) share price is ₹1442.2. It is down -15.27% from its 52 Week High price of ₹1702.05
How much percentage Cipla Ltd is up from its 52 Week low?
Cipla Ltd (CIPLA) share price is ₹1442.2. It is up 9.49% from its 52 Week Low price of ₹1317.25